Clinical Trial Update: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TQB2450 with anlotinib as second-line treatment for advanced biliary cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Biliary Cancer | Phase 3 | Status: UNKNOWN